WEKO3
アイテム
複合内分泌療法のラットDMBA誘発乳癌に対する抗腫瘍効果と内分泌動態
https://kindai.repo.nii.ac.jp/records/2002454
https://kindai.repo.nii.ac.jp/records/2002454c48418e8-f61b-4a04-a548-a10205169568
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AN00063584-19920325-0037.pdf (2.6 MB)
|
|
| Item type | ☆紀要論文 / Departmental Bulletin Paper(1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-02-19 | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | 複合内分泌療法のラットDMBA誘発乳癌に対する抗腫瘍効果と内分泌動態 | |||||||||||||
| 言語 | ja | |||||||||||||
| タイトル | ||||||||||||||
| タイトル | Antitumor effects and endocrine behavior of combined hormonal therapy on DMBA-induced rat mammary carcinomas | |||||||||||||
| 言語 | en | |||||||||||||
| 著者 |
門田, 今日子
× 門田, 今日子
× 和田, 富雄
|
|||||||||||||
| 言語 | ||||||||||||||
| 言語 | jpn | |||||||||||||
| キーワード | ||||||||||||||
| 主題 | combined hormonal therapy, DMBA-induced rat mammary tumor, antitumor effect, estrogen, endocrine behavior | |||||||||||||
| 資源タイプ | ||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||
| 資源タイプ | departmental bulletin paper | |||||||||||||
| 出版タイプ | ||||||||||||||
| 出版タイプ | AM | |||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||
| 出版者 名前 | ||||||||||||||
| 出版者 | 近畿大学医学会 | |||||||||||||
| 言語 | ja | |||||||||||||
| bibliographic_information |
ja : 近畿大学医学雑誌 en : Medical Journal of Kinki University 巻 17, 号 1, p. 37-53, 発行日 1992-03-25 |
|||||||||||||
| ISSN | ||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||
| 収録物識別子 | 03858367 | |||||||||||||
| 内容記述 | ||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||
| 内容記述 | Antitumor effects of combined hormonal therapy was investigated on DMBA-induced rat mammary carcinomas. The hormonal agents and their daily doses were 0.5 mg/kg for aromatase inhibitor, CGS 16949A (CGS), 16 mg/kg for medroxyprogesterone acetate (MPA) and 0.4 mg/kg for antiestrogen, tamoxifen (TAM). These agents were administered for three weeks continuously. CGS was combined with MPA and TAM for comparison with these single administrations. Tumor size compared to the non-treated control taken as 100% was 34.5% in the CGS+TAM group, 55.3% in the TAM group, 57.6% in the MPA group and 58.2% in the CGS group. However, there was no significant antitumor effect in the CGS+MPA group i. e., 84.3%. This was supposed to be related to the change in estrogen receptor contents had been changed to negative in 66.7% in the CGS+TAM group after treatment, while no case showed any change in estrogen receptor contents in the CGS+MPA group. There was no great difference in level of blood estradiol between the CGS+TAM (3.5±0.5pg/ml) and the CGS+MPA group (3.2±0.2pg/ml). On the other hand, the level of blood prolactin was higher in the CGS+TAM group (14.8±3.1ng/ml) than the CGS+MPA group (3.4±0.4ng/ml). This indicates that rat mammary tumors should be more sensitive for estrogen than prolactin. In histological findings, clear atrophic change of tubular formation in the CGS+TAM group and slight atrophic change of tubular formation in the CGS+MPA group were observed. However, in the CGS+MPA group, the destruction of cell and necrosis frequently noted in the MPA alone group was not detected. When CGS and TAM were administered the same time, the antitumor effect was higher than when they were administered alone. However, the combination of CGS and MPA reduced the antitumor effect in spite of the significant decrease in the level of blood estradiol. These findings indicate that the level of estradiol in the cancer tissue is a more important factor than the level of blood for tumor growth in DMBA induced rat mammary tumors. | |||||||||||||
| 言語 | en | |||||||||||||
| 内容記述 | ||||||||||||||
| 内容記述タイプ | Other | |||||||||||||
| 内容記述 | 本文データはCiNiiから複製したものである。 | |||||||||||||
| 言語 | ja | |||||||||||||
